Ford C H, Casson A G
Cancer Chemother Pharmacol. 1986;17(3):197-208. doi: 10.1007/BF00256685.
Enhancing the discrimination between tumour and host has been an underlying goal of efforts to improve the diagnosis and treatment of cancer. Over the past 15 years considerable interest has focussed upon targeting systems designed to permit selective delivery of a variety of agents, including drugs, radioisotopes and toxins, to tumours, for both diagnosis and therapy. A vast body of information has accumulated on this subject, and considerable emphasis has been placed on the use of antibodies as carriers, as at present they offer the greatest clinical potential. Many targeting systems have been evaluated in vitro and in pre-clinical models, but few, with the exception of antibody-radioisotope conjugates, have been evaluated in patients. However, systematic evaluation of the therapeutic potential of immunoconjugates in the clinic is planned or already under way. While reviews of some individual aspects of antibody targeting do exist, there are none that encompass this entire field. Our objective is to fill this gap with a concise overview of antibody-mediated targeting for diagnostic and therapeutic applications.
增强肿瘤与宿主之间的区分度一直是改善癌症诊断和治疗努力的一个潜在目标。在过去15年里，相当多的关注集中在靶向系统上，这些系统旨在允许将包括药物、放射性同位素和毒素在内的多种制剂选择性地递送至肿瘤，用于诊断和治疗。关于这个主题已经积累了大量信息，并且相当强调使用抗体作为载体，因为目前它们具有最大的临床潜力。许多靶向系统已经在体外和临床前模型中进行了评估，但除了抗体 - 放射性同位素偶联物外，很少有在患者中进行评估。然而，正在计划或已经在临床中对免疫偶联物的治疗潜力进行系统评估。虽然确实存在关于抗体靶向某些个别方面的综述，但没有涵盖整个领域的综述。我们的目标是通过对用于诊断和治疗应用的抗体介导靶向进行简要概述来填补这一空白。
